pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,400 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1069Endpoints809BioPharma Dive312BioSpace241Fierce Biotech228onclive165raps86globenewswire health
therapy area
allOncology6412Rare Disease1520Cardiology1214Hematology1095Immunology1073Vaccines973Pulmonology
  • Hikma and Amarin's generic drug case heads to Supreme Court arguments
    When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications o…
    Endpoints · 4mo ago↗ source
  • Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
    The charges against Morens come after Congressional probes related to the origins of the virus that causes Covid-19.
    STAT · 4mo ago↗ source
  • STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
    The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
← prev
page 93 of 96
next →
73
fda recalls56
fda medwatch48
fda press30
942
Psychiatry & CNS757
Ophthalmology455
Pain424
Endocrinology & Metabolism402
Infectious Disease381
STAT · 4mo ago
↗ source
  • Rocket's PRV goes for $180M; Oruka targets $500M offering
    Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...
    Endpoints · 4mo ago↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
    The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…
    Endpoints · 4mo ago↗ source
  • Incyte claims double Phase 3 win in vitiligo, will file for approval
    Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...
    Endpoints · 4mo ago↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 4mo ago↗ source
  • STAT+: Google’s clinical director on AI challenges
    In this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.
    STAT · 4mo ago↗ source
  • Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
    The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma gia…
    Endpoints · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
    The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch up with drugmakers and patients
    STAT · 4mo ago↗ source
  • FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug
    The FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New inf…
    Endpoints · 4mo ago↗ source
  • Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market
    Devoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athena…
    Endpoints · 4mo ago↗ source
  • Adaptyv Bio reveals latest results in protein design competition
    RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…
    Endpoints · 4mo ago↗ source
  • Predicting consequences of new hepatitis B vaccine recs
    New data on public trust in science, AI and mental health, and other news from Morning Rounds
    STAT · 4mo ago↗ source
  • Lilly strikes second partnership this year for recombinase-based gene editing
    Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwire…
    Endpoints · 4mo ago↗ source
  • Galapagos spinout Coultreon raises $125M for new take on SIK inhibition
    Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune disea…
    Endpoints · 4mo ago↗ source
  • STAT+: Eli Lilly enlists AI startup for next-generation gene editors
    Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.
    STAT · 4mo ago↗ source
  • Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending
    Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to s…
    Endpoints · 4mo ago↗ source
  • Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
    Obesity patients taking the weight loss injection being developed by Boehringer Ingelheim lost nearly 17% of their weight after about a year and a half, the company said Tuesday. The results are mo…
    Endpoints · 4mo ago↗ source
  • Opinion: It’s time to seize the rare bipartisan opening to address microplastics
    “This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.
    STAT · 4mo ago↗ source
  • Opinion: Why do discussions about ‘brain health’ ignore mental illness?
    “Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K. Manji, Eric J. Nestler, and Patrick J. Kennedy.
    STAT · 4mo ago↗ source
  • STAT+: A giant question looms over GOP’s new Medicaid work requirements
    Coverage losses tied to Medicaid work requirements may not be tracked in every states.
    STAT · 4mo ago↗ source
  • STAT+: Google clinical director says AI can be a ‘bridge’ for people having a mental health crisis
    Google's clinical director Megan Bell Jones on how the company is addressing concerns over mental health impacts of its AI products.
    STAT · 4mo ago↗ source
  • New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project
    Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers of infected infants, new studies project.
    STAT · 4mo ago↗ source
  • Supreme Court grapples with multibillion-dollar wave of lawsuits over Roundup cancer claims
    The Supreme Court seemed divided Monday over whether to block thousands of lawsuits alleging the maker of the weedkiller Roundup failed to warn people it could cause cancer.
    STAT · 4mo ago↗ source